{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:22:24Z","timestamp":1793391744378,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T00:00:00Z","timestamp":1754697600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370171"],"award-info":[{"award-number":["82370171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","award":["2022YFS0191"],"award-info":[{"award-number":["2022YFS0191"]}],"id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>This study explores innovative therapeutic approaches for acute myeloid leukemia by examining the synergistic effects of the histone deacetylase inhibitor chidamide in combination with cytarabine. In both in vitro and in vivo models, the drug combination demonstrated significant synergism in combating acute myeloid leukemia. Transcriptomic analysis revealed that the combination treatment notably downregulates the MYC signaling pathway. Binding assays, including surface plasmon resonance, molecular docking, and molecular dynamics simulations, further demonstrated that chidamide directly interacts with the C-MYC protein, while cytarabine enhanced this interaction. Delving deeper into the mechanism, we identified <jats:italic>RRP9<\/jats:italic>\u2014an essential gene for ribosome biogenesis and a key player in acute myeloid leukemia prognosis\u2014as a critical component of the MYC pathway. It was confirmed that MYC regulates RRP9 expression. Functional assays showed that overexpression of RRP9 promoted acute myeloid leukemia cell proliferation and resistance to the chidamide-cytarabine combination, whereas RRP9 knockdown impaired rRNA synthesis, reduced nucleolar size, and diminished protein production. Ultimately, we found that chidamide combined with cytarabine effectively inhibit ribosome biogenesis in acute myeloid leukemia cells. These results underscore the therapeutic potential of targeting the MYC-RRP9 axis to disrupt ribosome biogenesis in acute myeloid leukemia, offering a promising avenue for acute myeloid leukemia treatment.<\/jats:p>","DOI":"10.1038\/s41419-025-07928-y","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T23:43:23Z","timestamp":1754696603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chidamide and cytarabine synergistically treat acute myeloid leukemia: inhibiting ribosome biogenesis via the MYC-RRP9 pathway"],"prefix":"10.1038","volume":"16","author":[{"given":"Qing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-6440","authenticated-orcid":false,"given":"Jingcao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-7830","authenticated-orcid":false,"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-9711","authenticated-orcid":false,"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,9]]},"reference":[{"key":"7928_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021;127:2049\u201361.","journal-title":"Cancer"},{"key":"7928_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98:502\u201326.","journal-title":"Am J Hematol"},{"key":"7928_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","volume":"45","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Konopleva M. AML treatment: conventional chemotherapy and emerging novel agents. Trends Pharm Sci. 2024;45:430\u201348.","journal-title":"Trends Pharm Sci"},{"key":"7928_CR4","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S2352-3026(22)00106-5","volume":"9","author":"H Wang","year":"2022","unstructured":"Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, et al. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022;9:e415\u2013e424.","journal-title":"Lancet Haematol"},{"key":"7928_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","volume":"401","author":"HP Erba","year":"2023","unstructured":"Erba HP, Montesinos P, Kim HJ, Patkowska E, Vrhovac R, Zak P, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1571\u201383.","journal-title":"Lancet"},{"key":"7928_CR6","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","volume":"10","author":"S Venugopal","year":"2024","unstructured":"Venugopal S, Sekeres MA. Contemporary Management of Acute Myeloid Leukemia: A Review. JAMA Oncol. 2024;10:1417\u201325.","journal-title":"JAMA Oncol"},{"key":"7928_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-023-01531-8","volume":"15","author":"G Lu","year":"2023","unstructured":"Lu G, Jin S, Lin S, Gong Y, Zhang L, Yang J, et al. Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL). Clin Epigenetics. 2023;15:124.","journal-title":"Clin Epigenetics"},{"key":"7928_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2017.04.037","volume":"90","author":"X Li","year":"2017","unstructured":"Li X, Yan X, Guo W, Huang X, Huang J, Yu M, et al. Chidamide in FLT3-ITD positive acute myeloid leukemia and the synergistic effect in combination with cytarabine. Biomed Pharmacother. 2017;90:699\u2013704.","journal-title":"Biomed Pharmacother"},{"key":"7928_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-017-0377-8","volume":"9","author":"Y Li","year":"2017","unstructured":"Li Y, Wang Y, Zhou Y, Li J, Chen K, Zhang L, et al. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Clin Epigenetics. 2017;9:83.","journal-title":"Clin Epigenetics"},{"key":"7928_CR10","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3389\/fonc.2019.01276","volume":"9","author":"H Huang","year":"2019","unstructured":"Huang H, Wenbing Y, Dong A, He Z, Yao R, Guo W. Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels. Front Oncol. 2019;9:1276.","journal-title":"Front Oncol"},{"key":"7928_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01911-9","volume":"40","author":"Y Wei","year":"2023","unstructured":"Wei Y, Wang L, Zhu C, Li H, Bo J, Zhang R, et al. A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Med Oncol. 2023;40:77.","journal-title":"Med Oncol"},{"key":"7928_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-020-00923-4","volume":"12","author":"L Wang","year":"2020","unstructured":"Wang L, Luo J, Chen G, Fang M, Wei X, Li Y, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed\/refractory acute myeloid leukemia: a single-arm, phase 1\/2 study. Clin Epigenetics. 2020;12:132.","journal-title":"Clin Epigenetics"},{"key":"7928_CR13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.bcp.2018.11.014","volume":"159","author":"F Catez","year":"2019","unstructured":"Catez F, Dalla Venezia N, Marcel V, Zorbas C, Lafontaine DLJ, Diaz JJ. Ribosome biogenesis: An emerging druggable pathway for cancer therapeutics. Biochem Pharm. 2019;159:74\u201381.","journal-title":"Biochem Pharm"},{"key":"7928_CR14","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","volume":"82","author":"AR Elhamamsy","year":"2022","unstructured":"Elhamamsy AR, Metge BJ, Alsheikh HA, Shevde LA, Samant RS. Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance. Cancer Res. 2022;82:2344\u201353.","journal-title":"Cancer Res"},{"key":"7928_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbae023","volume":"25","author":"Y Zang","year":"2024","unstructured":"Zang Y, Ran X, Yuan J, Wu H, Wang Y, Li H, et al. Genomic hallmarks and therapeutic targets of ribosome biogenesis in cancer. Brief Bioinform. 2024;25:bbae023.","journal-title":"Brief Bioinform"},{"key":"7928_CR16","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3324\/haematol.2022.280831","volume":"107","author":"MP Garcia-Cuellar","year":"2022","unstructured":"Garcia-Cuellar MP, Prinz A, Slany RK. Meis1 supports leukemogenesis through stimulation of ribosomal biogenesis and Myc. Haematologica. 2022;107:2601\u201316.","journal-title":"Haematologica"},{"key":"7928_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206098","volume":"10","author":"J Xu","year":"2023","unstructured":"Xu J, Zhong A, Zhang S, Chen M, Zhang L, Hang X, et al. KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis Inhibition. Adv Sci (Weinh). 2023;10:e2206098.","journal-title":"Adv Sci (Weinh)"},{"key":"7928_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.semcdb.2022.04.001","volume":"136","author":"MC Lafita-Navarro","year":"2023","unstructured":"Lafita-Navarro MC, Conacci-Sorrell M. Nucleolar stress: From development to cancer. Semin Cell Dev Biol. 2023;136:64\u201374.","journal-title":"Semin Cell Dev Biol"},{"key":"7928_CR19","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrc1885","volume":"6","author":"S Grisendi","year":"2006","unstructured":"Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6:493\u2013505.","journal-title":"Nat Rev Cancer"},{"key":"7928_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18:51\u201363.","journal-title":"Nat Rev Cancer"},{"key":"7928_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/biom10050783","volume":"10","author":"S Ojha","year":"2020","unstructured":"Ojha S, Malla S, Lyons SM. snoRNPs: Functions in Ribosome Biogenesis. Biomolecules. 2020;10:783.","journal-title":"Biomolecules"},{"key":"7928_CR22","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1093\/nar\/gkaa066","volume":"48","author":"G Clerget","year":"2020","unstructured":"Clerget G, Bourguignon-Igel V, Marmier-Gourrier N, Rolland N, Wacheul L, Manival X, et al. Synergistic defects in pre-rRNA processing from mutations in the U3-specific protein Rrp9 and U3 snoRNA. Nucleic Acids Res. 2020;48:3848\u201368.","journal-title":"Nucleic Acids Res"},{"key":"7928_CR23","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u2013W560.","journal-title":"Nucleic Acids Res"},{"key":"7928_CR24","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood.2021013156","volume":"139","author":"CP Mill","year":"2022","unstructured":"Mill CP, Fiskus W, DiNardo CD, Birdwell C, Davis JA, Kadia TM, et al. Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. Blood. 2022;139:907\u201321.","journal-title":"Blood"},{"key":"7928_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106700","volume":"189","author":"Y Han","year":"2023","unstructured":"Han Y, Hu A, Qu Y, Xu Q, Wang H, Feng Y, et al. Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia. Pharmacol Res. 2023;189:106700.","journal-title":"Pharmacol Res"},{"key":"7928_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","volume":"9","author":"A Khot","year":"2019","unstructured":"Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, et al. First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discov. 2019;9:1036\u201349.","journal-title":"Cancer Discov"},{"key":"7928_CR27","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.3390\/ijms21114037","volume":"21","author":"F Destefanis","year":"2020","unstructured":"Destefanis F, Manara V, Bellosta P. Myc as a Regulator of Ribosome Biogenesis and Cell Competition: A Link to Cancer. Int J Mol Sci. 2020;21:4037.","journal-title":"Int J Mol Sci"},{"key":"7928_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc2819","volume":"10","author":"J van Riggelen","year":"2010","unstructured":"van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10:301\u20139.","journal-title":"Nat Rev Cancer"},{"key":"7928_CR29","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood.2021013201","volume":"139","author":"ML Amaya","year":"2022","unstructured":"Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood. 2022;139:584\u201396.","journal-title":"Blood"},{"key":"7928_CR30","doi-asserted-by":"publisher","first-page":"e005871","DOI":"10.1136\/jitc-2022-005871","volume":"11","author":"V Marquardt","year":"2023","unstructured":"Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blumel L, et al. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. J Immunother Cancer. 2023;11:e005871.","journal-title":"J Immunother Cancer"},{"key":"7928_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1073\/pnas.49.1.122","volume":"49","author":"JR Warner","year":"1963","unstructured":"Warner JR, Knopf PM, Rich A. A multiple ribosomal structure in protein synthesis. Proc Natl Acad Sci USA. 1963;49:122\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7928_CR32","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H Dohner","year":"2021","unstructured":"Dohner H, Wei AH, Lowenberg B. Towards precision medicine for AML. Nat Rev Clin Oncol. 2021;18:577\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"7928_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40164-022-00282-1","volume":"11","author":"H Zhao","year":"2022","unstructured":"Zhao H, Jiang Y, Lin F, Zhong M, Tan J, Zhou Y, et al. Chidamide and apatinib are therapeutically synergistic in acute myeloid leukemia stem and progenitor cells. Exp Hematol Oncol. 2022;11:29.","journal-title":"Exp Hematol Oncol"},{"key":"7928_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40164-023-00383-5","volume":"12","author":"S Gu","year":"2023","unstructured":"Gu S, Hou Y, Dovat K, Dovat S, Song C, Ge Z. Synergistic effect of HDAC inhibitor Chidamide with Cladribine on cell cycle arrest and apoptosis by targeting HDAC2\/c-Myc\/RCC1 axis in acute myeloid leukemia. Exp Hematol Oncol. 2023;12:23.","journal-title":"Exp Hematol Oncol"},{"key":"7928_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.569651","volume":"11","author":"L Lin","year":"2020","unstructured":"Lin L, Que Y, Lu P, Li H, Xiao M, Zhu X, et al. Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK\/ERK Signaling Pathway. Front Pharm. 2020;11:569651.","journal-title":"Front Pharm"},{"key":"7928_CR36","first-page":"1133","volume":"135","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li J, Xu H, Shao X, Fu L, Hou Y, et al. Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpalpha and Cebpdelta. Blood. 2020;135:1133\u201345.","journal-title":"Blood"},{"key":"7928_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102154","volume":"94","author":"MJ Duffy","year":"2021","unstructured":"Duffy MJ, O\u2019Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.","journal-title":"Cancer Treat Rev"},{"key":"7928_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-022-01285-4","volume":"8","author":"L Jiao","year":"2023","unstructured":"Jiao L, Liu Y, Yu XY, Pan X, Zhang Y, Tu J, et al. Ribosome biogenesis in disease: new players and therapeutic targets. Signal Transduct Target Ther. 2023;8:15.","journal-title":"Signal Transduct Target Ther"},{"key":"7928_CR39","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021109823","volume":"41","author":"JR Kovalski","year":"2022","unstructured":"Kovalski JR, Kuzuoglu-Ozturk D, Ruggero D. Protein synthesis control in cancer: selectivity and therapeutic targeting. EMBO J. 2022;41:e109823.","journal-title":"EMBO J"},{"key":"7928_CR40","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1016\/j.molcel.2021.08.033","volume":"81","author":"L Sun","year":"2021","unstructured":"Sun L, Wang W, Han C, Huang W, Sun Y, Fang K, et al. The oncomicropeptide APPLE promotes hematopoietic malignancy by enhancing translation initiation. Mol Cell. 2021;81:4493\u2013508.","journal-title":"Mol Cell"},{"key":"7928_CR41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood.2021012629","volume":"139","author":"JE Messling","year":"2022","unstructured":"Messling JE, Agger K, Andersen KL, Kromer K, Kuepper HM, Lund AH, et al. Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia. Blood. 2022;139:245\u201355.","journal-title":"Blood"},{"key":"7928_CR42","first-page":"51455","volume":"87","author":"V Gandin","year":"2014","unstructured":"Gandin V, Sikstrom K, Alain T, Morita M, McLaughlan S, Larsson O, et al. Polysome fractionation and analysis of mammalian translatomes on a genome-wide scale. J Vis Exp. 2014;87:51455.","journal-title":"J Vis Exp"},{"key":"7928_CR43","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/cells9041061","volume":"9","author":"O Sergeeva","year":"2020","unstructured":"Sergeeva O, Sergeev P, Melnikov P, Prikazchikova T, Dontsova O, Zatsepin T. Modification of Adenosine196 by Mettl3 Methyltransferase in the 5\u2019-External Transcribed Spacer of 47S Pre-rRNA Affects rRNA Maturation. Cells. 2020;9:1061.","journal-title":"Cells"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07928-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07928-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:49:19Z","timestamp":1757346559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07928-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7928"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07928-y","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,9]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The extraction of primary AML cells was approved by the Ethics Committee of West China Hospital, Sichuan University (approval number: 2019 (114)). The animal experiments were approved by the Ethics Committee of West China Hospital, Sichuan University (approval number: 2020232\u2009A). All methods involving human samples and animals were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All human-related experiments in this study, including the use of human tissue samples, were conducted with the written informed consent of all participants or sample donors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"601"}}